Q4 2018 · —
Revenue—
Net Income-$450.00-$450.00 no prior Q4 2017 on fileN/M vs Q3 2018
EPS Diluted$0.00$0.00 no prior Q4 2017 on fileN/M vs Q3 2018
Operating Cash Flow-$450—
Free Cash Flowderived-$12,649,000—
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
no prior Q4 2017 on file
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR